Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 13/20 | 0.69 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | CTSV | O60911 | 1/20 | 0.51 |
| ▸ | CTSL | P07711 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4957735 | 0.86 | BRD4 (0.69) | BRD4CYP19A1MEN1KMT2AKDM4E | |
| SCHEMBL6948195 | 0.83 | BRD4 (0.74) | BRD4CYP19A1MEN1KMT2AGAA | |
| SCHEMBL8924076 | 0.82 | BRD4 (1.00) | BRD4CYP19A1MEN1KMT2A | |
| SCHEMBL9732666 | 0.82 | BRD4 (0.72) | BRD4CYP19A1MEN1KMT2A | |
| SCHEMBL6947577 | 0.81 | BRD4 (0.67) | BRD4CYP19A1MEN1KMT2AGAA | |
| SCHEMBL2460978 | 0.81 | LMNA (0.49) | BRD4MEN1KMT2AGAAKDM4E | |
| SCHEMBL10659617 | 0.81 | BRD4 (0.70) | BRD4CYP19A1MEN1KMT2AKDM4E | |
| SCHEMBL7649327 | 0.81 | BRD4 (0.70) | BRD4CYP19A1MEN1KMT2AKDM4E | |
| SCHEMBL7646955 | 0.81 | BRD4 (0.74) | BRD4CYP19A1MEN1KMT2AGAA | |
| SCHEMBL5399487 | 0.81 | BRD4 (0.70) | BRD4CYP19A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100197744-A1 | Organic Compounds | BARNES DAVID | 2010-08-05 | — | — | US | disclosed |
| CN-101687828-A | Thiadiazole derivatives as antidiabetic agents | NOVARTIS AG | 2010-03-31 | — | — | CN | disclosed |
| EP-2155704-A1 | THIADIAZOLE DERIVATIVES AS ANTIDIABETIC AGENTS | Novartis Ag (CH) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008148744-A1 | THIADIAZOLE DERIVATIVES AS ANTIDIABETIC AGENTS | NOVARTIS AG (CH) | 2008-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197744-A1 | Organic Compounds | PTPRS, PTPRO, PTPRC | BRD4 2315/4885CYP19A1 2070/4885MEN1 4409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.